For the quarter ended September 2026, TG Therapeutics (TGTX Quick QuoteTGTX - Free Report) reported revenue of $259.94 million, up 60.7% over the same period last year. EPS came in at $0.35, compared to $2.43 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $247.16 million, representing a surprise of +5.17%. The company delivered an EPS surprise of +25%, with the consensus EPS estimate being $0.28.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how TG Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Product revenue, net: $240.04 million versus the three-analyst average estimate of $242.46 million.
• Revenue- License, milestone, royalty and other: $19.89 million versus $4.71 million estimated by three analysts on average.
• Product revenue- BRIUMVI - U.S.: $233 million versus the two-analyst average estimate of $236.23 million.

View all Key Company Metrics for TG Therapeutics here>>>

Shares of TG Therapeutics have returned +8.1% over the past month versus the Zacks S&P 500 composite's -5.6% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.